A Spliced Antigenic Peptide Comprising a Single Spliced Amino Acid Is Produced in the Proteasome by Reverse Splicing of a Longer Peptide Fragment followed by Trimming.
Requirement of tumor-associated antigen-specific CD4+ T cells for an efficient dendritic cell vaccine in antitumor immunotherapy.
Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells.
Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells.
MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge.
Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas.
Purification of circulating plasmacytoid dendritic cells using counterflow centrifugal elutriation and immunomagnetic beads.
Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi.
Human dendritic cells sequentially matured with CD4(+) T cells as a secondary signal favor CTL and long-term T memory cell responses.
Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth.
Dendritic cell preparation for immunotherapeutic interventions.
A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes.
A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.
Synthesis of glycocluster-tumor antigenic peptide conjugates for dendritic cell targeting.
Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells.
Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity.
A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy.
Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells.
Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus.
Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells.
Interactions between dead cells and dendritic cells in the induction of antiviral CTL responses.
Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells.
Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells.
Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells.
Dendritic cell-dead cell interactions: implications and relevance for immunotherapy.
Dendritic cells resurrect antigens from dead cells.
EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function.
Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients.
Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells.
High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells.
Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues.
Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
LFA-3 co-stimulates cytokine secretion by cytotoxic T lymphocytes by providing a TCR-independent activation signal.
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
Heterogeneity of biologic responses of melanoma-specific CTL.
Identification of a gp100 epitope recognized by HLA-A3 restricted melanoma infiltrating lymphocytes.
Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription.
[Cecal plasmocytosarcoma appearing after 4 years of development of multiple myeloma]
Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells.
New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.
Antitumor Virotherapy by Attenuated Measles Virus (MV).
A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.
Recognition of pleural mesothelioma by mucin-1(950-958)/human leukocyte antigen A*0201-specific CD8+ T-cells.
Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells.
Cross-presentation of cell-associated antigens by dendritic cells.